{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-065459","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.379618+00:00","generated_at":"2026-06-18T07:17:07.795635+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BridgeBio Pharma prices $150M public offering of common stock at $17.00/share","bullets":["Offering of 8,823,530 shares (plus underwriters' 30-day option for 1,323,529 shares) at $17.00/share.","Gross proceeds ~$150M; net proceeds ~$143.1M after underwriting discounts and expenses.","Expected use of proceeds: fund clinical/pre-clinical development, research, working capital, and potential acquisitions.","Expected closing on or around March 10, 2023.","Goldman Sachs, Evercore, Morgan Stanley, and KKR Capital Markets are book-running managers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-065459","json":"https://secwatch.observer/filing/0001193125-23-065459.json","markdown":"https://secwatch.observer/filing/0001193125-23-065459.md","text":"https://secwatch.observer/filing/0001193125-23-065459.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000119312523065459/0001193125-23-065459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000119312523065459/d463641d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:17:07.795635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f02896a20a5c246da35fa31866524005a0a417fc","claim":"BridgeBio Pharma, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC valued at $17.00 per share (effective 2023-03-07).","evidence_excerpt":"On March 7, 2023, BridgeBio Pharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC, as representatives of the several underwriters listed on Schedule I thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 8,823,530 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at a price to the public of $17.00 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000119312523065459/0001193125-23-065459-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC"},{"label":"Value","value":"$17.00 per share"},{"label":"Effective","value":"2023-03-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}